天山生物 reported revenue of ¥0.22B for the period ended 2026-06-30, +427.7% year on year. Net income was ¥0.01B, a 2.4% net margin on a 9.1% gross margin. The largest revenue line is 肉类 at 60% of the total. Free cash flow for the period was ¥0.00B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.22B | +427.7% |
| Gross profit | ¥0.02B | — |
| Operating income | ¥0.01B | — |
| Net income | ¥0.01B | — |
| Gross margin | 9.1% | Net margin 2.4% |
| Revenue Q/Q | -14.8% | — |
| Segment | Revenue | Share |
|---|---|---|
| 肉类 | ¥0.13B | 60.1% |
| 饲料 | ¥0.03B | 13.7% |
| 活畜 | ¥0.03B | 11.6% |
| 土地租赁 | ¥0.02B | 9.7% |
| 冻精 | ¥0.01B | 3.8% |
| 其他(补充) | ¥0.00B | 1.1% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.20B | 90.9% |
| R&D | ¥0.00B | 0.1% |
| SG&A | ¥0.01B | 6.4% |
| Tax & other | ¥0.00B | 0.8% |
| Item | Amount |
|---|---|
| Total assets | ¥0.29B |
| Total liabilities | ¥0.24B |
| Shareholders' equity | ¥0.05B |
| Equity / assets | 18.0% |
| Operating cash flow | ¥0.00B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥0.00B |
| Cash conversion (OCF / net income) | -210% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
戴维医疗 ・ 掌趣科技 ・ 珈伟新能 ・ 博晖创新 ・ 麦捷科技 ・ 海达股份 ・ 同大股份 ・ 硕贝德 ・ 华灿光电 ・ 旋极信息 ・ ST凯利 ・ 中颖电子
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies